Virus-Hijacking COVID-19 Drug from Gladstone Researchers Slows Down Variants, Expects Clinical Trial Early Next Year
Virus-Hijacking COVID-19 Drug from Gladstone Researchers Slows Down Variants, Expects Clinical Trial Early Next Year
San Francisco Business Times—Senior Investigator Leor Weinberger, PhD, pioneered a new class of antivirals called therapeutic interfering particles (TIPs), which were recently shown to be effective against SARS-CoV-2 in animal models. The approach is now being developed by a startup company and will be headed to clinical trials.
Gladstone Experts COVID-19 Center for Cell Circuitry Virology Weinberger Lab